Effect of fluoxetine on an experimental model of diabetes-induced neuropathic pain perception in the rat

Indian Journal of Pharmaceutical Sciences

Volumn 73, Issue 6, 2011, Pages 621-625

  Tembhurne, S ^a   Sakarkar, D ^a  

^a Sudhakarrao Naik Institute of Pharmacy   (India)

Author keywords

Diabetic neuropathy; diabeties mellitus; pain perception and fluoxetine

Indexed keywords

FLUOXETINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; GRIP STRENGTH; MALE; NERVE INJURY; NEUROPROTECTION; NOCICEPTION; NONHUMAN; RAT; TREATMENT DURATION;

EID: 84866237702     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.100235     Document Type: Article

References (21)

1. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabetes Med 1998;15:97-112.
2. Mark AR. Neuropathies associated with diabetes. Med Clin North Am 1993;27:111-24.
3. Rai S, Gupta A, Rai M, Birari KV. Diabetic peripheral neuropathyemerging pharmacologic options. Bombay Hosp J 2008;50:595
4. Boulton AJ, Malik AR, Arezzo CJ, Sosenko MJ. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86.
5. Ardid D, Guilbaund G. Antinociceptive effects of acute and chronic injection of tricyclic antidepressants drugs in a new model of mono neuropathy in rats. Pain 1992;49:279-87.
6. Duby JJ, Campbell K, Setter SM. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm 2004;61:160-76.
7. Apfel SC, Kessler JA. Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres Clin Neurol 1995;4:593-606.
8. Ziegler D. In: 16th Annual Neurodiab Meeting. Ystad, Sweden. Antioxidant treatment in diabetic polneuropathy-update 2006.
9. Zareba G. Pregabalin: A new agent for the treatment of neuropathic pain. Drugs Today 2005;41:509-16.
10. Fields HL, Heinricher MM, Mason P. Neurotransmitter in nociceptive modulatory circuits. Ann Rev Neurosci 1991;14:219-45.
11. Lear J, Burden AC. Fluoxetine side-effects mimicking hypoglycaemia. Lancet 1992;339:1296.
12. Deeg MA, Lipkin EW. Hypoglycemia associated with the use of fluoxetine. West J Med 1996;164:262-3.
13. Talha J, Shakya AK, Mehnaz K, Hussain S. Amitriptyline and Sertraline in Diabetic Neuropathy: A Comparative View. Int J Health Res 2008;1:73-8.
14. D'Amour WL, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941;72:74.
15. Sawynok J, Reid AR, Esser MJ. Periphreal antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain 1999;82:149-55.
16. Braham D, Trinder P. An improved color reaction for the determination of blood glucose by oxidase system. Analyst 1972;97:142-4.
17. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature. Harv Rev Psychiatry 2000;7:257-77.
18. Raz I, Hasdi D, Seltzer, Melmed RN. Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes 1988;37:1253-9.
19. Simon GS, Dewey WL. Effect of streptozotocin induced diabeties on the antinociceptive potency of Morphine. J Pharmacol Exp Ther 1981;218:318-23.
20. Ochoa JL. Pain mechanism in neuropathy. Curr Opin Neurol 1994;7:407-14.
21. Kurlekar PN, Bhatt JD. Study of the antinociceptive activity of fluoxetine and its interaction with morphine and naloxone in mice. Indian J Pharmacol 2004;36:369-72.